SCM
HOWL icon

Soleus Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Soleus Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-64,585
Closed -$769K – 75
2021
Q4 		$769K Sell
64,585
-498,811
-89% -$7.53M 0.08% 62
2021
Q3 		$9.67M Hold
563,396
– – 1.51% 20
2021
Q2 		$9.83M Buy
+563,396
New +$7.72M 1.51% 20

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Soleus Capital Management's HOWL Position: Q1 2022 in Review

Soleus Capital Management sold out of Werewolf Therapeutics (HOWL) in Q1 2022, closing a stake of 64,585 shares — an estimated $769K sold.

Soleus Capital Management first reported a position in HOWL in Q2 2021 and held it in 3 quarters. The position peaked at $9.83M in Q2 2021. 49 funds tracked by Wall St. Rank hold HOWL as of Q1 2022.

  • Soleus Capital Management reported no remaining Werewolf Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Soleus Capital Management sold 64,585 Werewolf Therapeutics shares in Q1 2022, an estimated $769K.
  • Soleus Capital Management first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 3 quarters.
  • Soleus Capital Management's Werewolf Therapeutics position peaked at $9.83M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2022.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.